Novo Raises 2026 Outlook as Q3 Adjusted Operating Profit Jumps 27% at CER
NVO sits 22% above its 52-week low of $35.12.
Summary
Novo raised 2026 guidance to -2% to +2% at CER and lifted free cash flow guidance to DKK 60-70 billion, with Q3 adjusted operating profit up 27% at CER. Reported profit fell 9% on DKK 8.7 billion of impairments, and the company announced a CFO change plus steep US list price cuts from January 2027.
Key Events · Earnings and Guidance · NVO
-
2026 Guidance Raised to -2% to +2%
Adjusted sales and adjusted operating profit growth are now seen at -2% to +2% at CER, up from -6% to 0%, driven by higher GLP-1 sales expectations in both operating units.
-
Q3 Adjusted Operating Profit Up 27%
Adjusted operating profit was DKK 31,720 million, up 27% at CER, on net sales of DKK 79,195 million (+4% at CER). Reported operating profit fell 9% at CER after DKK 8.7 billion of non-cash impairments.
-
Free Cash Flow Guidance Lifted
Free cash flow is now expected at DKK 60-70 billion versus DKK 45-55 billion previously, with capital expenditure cut to around DKK 50 billion from around DKK 55 billion.
-
US List Prices Cut From January 2027
Wegovy and Ozempic list prices fall to USD 675 effective 1 January 2027, roughly 50% and 35% reductions respectively, which Novo says will affect 2027 cash flow.
Analysis · NVO · Life Sciences
Novo lifted full-year guidance to -2% to +2% at CER for both adjusted sales and adjusted operating profit, up from -6% to 0%, and raised the free cash flow range to DKK 60-70 billion from DKK 45-55 billion. Underneath, the quarter was messy: reported operating profit fell 9% at CER because of DKK 8.7 billion of non-cash impairments on ziltivekimab and manufacturing right-sizing, so the headline beat rests on adjusted numbers that strip those out. Two other items matter for the thesis. Novo will cut US list prices for Wegovy and Ozempic to USD 675 effective 1 January 2027, roughly 50% and 35% reductions, which pressures 2027 revenue per prescription even as it supports volume and access. And CFO Karsten Munk Knudsen departs at end-December after 27 years, with ex-Galderma CFO Luigi La Corte replacing him.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVO was trading at $42.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $178.8B. The 52-week trading range was $35.12 to $64.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.